BridgeBio Pharma (BBIO) Non-Current Debt (2018 - 2026)

BridgeBio Pharma has disclosed Non-Current Debt across 9 years of filings, most recently posting $741.4 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $741.4 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $741.4 million (changed N/A YoY), and the FY2025 annual result was $564.6 million, up 3.56% from the prior year.
• Non-Current Debt came in at $741.4 million for Q1 2026 at BridgeBio Pharma, up from $564.6 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $741.4 million in Q1 2026 to a low of $418.4 million in Q2 2022.
• The 5-year median for Non-Current Debt is $436.2 million (2024), against an average of $491.3 million.
• Across the five-year window, Non-Current Debt surged 378.3% in 2022 and dropped 1.25% in 2024, its largest moves.
• BridgeBio Pharma's Non-Current Debt stood at $431.0 million in 2022, then gained by 3.59% to $446.4 million in 2023, then grew by 22.11% to $545.2 million in 2024, then gained by 3.56% to $564.6 million in 2025, then jumped by 31.32% to $741.4 million in 2026.
• The last three Non-Current Debt figures came in at $741.4 million (Q1 2026), $564.6 million (Q4 2025), and $740.4 million (Q3 2025), per Business Quant data.